A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

被引：0

作者：

Elizabeth Berry-Kravis

Randi Hagerman

Dejan Budimirovic

Craig Erickson

Helen Heussler

Nicole Tartaglia

Jonathan Cohen

Flora Tassone

Thomas Dobbins

Elizabeth Merikle

Terri Sebree

Nancy Tich

Joseph M. Palumbo

Stephen O’Quinn

机构：

[1] Rush University Medical Center,Departments of Pediatrics and Neurological Sciences

[2] University of California-Davis Medical Center,Medical Investigation of Neurodevelopmental Disorders (MIND) Institute

[3] University of California Davis School of Medicine,Department of Pediatrics

[4] Fragile X Clinic,Departments of Psychiatry and Child Psychiatry

[5] Kennedy Krieger Institute/the Johns Hopkins Medical Institutions,Department of Psychiatry and Behavioral Neuroscience

[6] Department of Psychiatry & Behavioral Sciences-Child Psychiatry,Centre for Clinical Trials in Rare Neurodevelopmental Disorders

[7] Johns Hopkins School of Medicine,Department of Pediatrics, Developmental Pediatrics

[8] Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine,Department of Biochemistry and Molecular Medicine, School of Medicine

[9] Children’s Health Queensland,undefined

[10] Centre for Child Health Research,undefined

[11] University of Queensland,undefined

[12] University of Colorado School of Medicine,undefined

[13] Children’s Hospital Colorado,undefined

[14] Fragile X Alliance Inc,undefined

[15] North Caulfield,undefined

[16] Centre for Developmental Disability Health Victoria,undefined

[17] Monash University,undefined

[18] University of California-Davis,undefined

[19] The Griesser Group,undefined

[20] Labcorp Drug Development,undefined

[21] Zynerba Pharmaceuticals Inc.,undefined

来源：

Journal of Neurodevelopmental Disorders | 2022年 / 14卷

关键词：

Fragile X syndrome; Clinical trial; Endocannabinoid system; Cannabidiol;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 246 条

[1]

Coffee B(2009)Incidence of fragile X syndrome by newborn screening for methylated Am J Hum Genet 85 503-514

[2]

Keith K(1997) DNA West J Med. 166 129-37

[3]

Albizua I(2011)Fragile X syndrome. Molecular and clinical insights and treatment issues Dev Neurosci 33 337-348

[4]

Malone T(1991)The psychiatric presentation of fragile X: evolution of the diagnosis and treatment of the psychiatric comorbidities of fragile X syndrome Cell 65 905-914

[5]

Mowrey J(1991)Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome Cell 66 817-822

[6]

Sherman SL(1992)Absence of expression of the FMR-1 gene in fragile X syndrome Hum Mol Genet 1 397-400

[7]

Hagerman RJ(2019)DNA methylation represses FMR-1 transcription in fragile X syndrome Brain Sci. 9 96-1536

[8]

Tranfaglia MR(2013)Molecular biomarkers in fragile X syndrome Nat Neurosci 16 1530-1032

[9]

Verkerk AJ(2020)The translation of translational control by FMRP: therapeutic targets for FXS Brain Sci 10 694-179

[10]

Pieretti M(2017)A genotype-phenotype study of high-resolution Nat Rev Dis Primers 3 17065-462

← 1 2 3 4 5 6 7 8 9 10 →